 | |
| Clinical data | |
|---|---|
| Other names | SHR-6390 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H30N6O2 |
| Molar mass | 446.555 g·mol−1 |
Dalpiciclib is a drug for the treatment of various forms of cancer. [1]
In China, dalpiciclib is approved for use in combination with fulvestrant for treatment of HR-positive, HER2-negative recurrent, or metastatic breast cancer in patients who have progressed after previous endocrine therapy. [2]
Dalpicicilib is a CDK inhibitor that targets the CDK4 and CDK6 isoforms. [3]
References
- ^ Chen X, Shen K (June 2023). "Dalpiciclib in advanced breast cancer". The Lancet. Oncology. 24 (6): 578–579. doi: 10.1016/S1470-2045(23)00228-0. PMID 37269836.
- ^ "Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer". hengrui.com.
- ^ Sheikh MS, Satti SA (2021). "The emerging CDK4/6 inhibitor for breast cancer treatment". Molecular and Cellular Pharmacology. 13 (3): 9–12. PMC 8896653. PMID 35251463.
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |